Livzon Pharmaceutical Group Inc. (HKG:1513)

HKG:1513 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Jan 1, 2021
Cash & Equivalents	9,919	10,827	11,326	10,411	9,146	9,954
Trading Asset Securities	1,126	89.36	81.79	108.09	182.77	25.98
Cash & Short-Term Investments	11,045	10,917	11,408	10,519	9,329	9,980
Cash Growth	2.18%	-4.30%	8.44%	12.76%	-6.52%	12.48%
Accounts Receivable	3,278	3,249	3,575	4,039	3,294	2,892
Other Receivables	52.98	59.28	51.91	31.32	64.37	92.85
Receivables	3,331	3,308	3,627	4,071	3,358	2,985
Inventory	1,657	1,998	2,061	2,045	1,663	1,488
Other Current Assets	540.01	197.44	171.11	352	322.42	174.88
Total Current Assets	16,572	16,420	17,266	16,987	14,673	14,627
Property, Plant & Equipment	4,358	4,537	4,566	4,592	4,239	3,707
Long-Term Investments	1,645	1,618	1,670	1,738	1,695	988.09
Goodwill	124.91	124.91	124.91	103.04	103.04	103.04
Other Intangible Assets	478.72	403.68	426.28	557.44	260.28	236.43
Long-Term Deferred Tax Assets	416.2	356.35	301.92	283.89	252.69	238.23
Long-Term Deferred Charges	516.92	396.25	468.62	416.74	704.41	373.49
Other Long-Term Assets	425.62	599.54	221.17	189.66	444.62	317.09
Total Assets	24,538	24,456	25,045	24,868	22,372	20,591
Accounts Payable	1,304	1,584	1,658	1,862	1,817	1,625
Accrued Expenses	301.13	3,109	3,295	3,249	2,656	2,467
Short-Term Debt	2,440	2,455	1,860	1,622	2,043	1,551
Current Portion of Long-Term Debt	106.31	36.21	647.47	-	-	-
Current Portion of Leases	-	12.53	12.2	10.44	9.28	8.54
Current Income Taxes Payable	261.23	112.88	181.58	92.57	97.45	179.51
Current Unearned Revenue	69.22	124.63	138	226.19	167.8	104.45
Other Current Liabilities	2,877	191.27	294.49	334.42	134.34	147.17
Total Current Liabilities	7,358	7,625	8,087	7,397	6,925	6,083
Long-Term Debt	1,357	1,466	1,613	1,974	636.78	360.32
Long-Term Leases	13.98	13.1	9.03	11.61	5.27	10.1
Long-Term Unearned Revenue	231.18	238.42	269.37	273.21	258.88	276.14
Long-Term Deferred Tax Liabilities	210.49	207.39	209.81	191.96	156.89	143.28
Other Long-Term Liabilities	-	-	90	84	78	78
Total Liabilities	9,171	9,550	10,278	9,932	8,061	6,951
Common Stock	904.1	911.35	923.94	935.55	937.87	944.84
Additional Paid-In Capital	298.83	529.24	1,322	1,422	1,629	1,457
Retained Earnings	13,271	12,506	11,653	11,182	10,461	9,682
Treasury Stock	-570.31	-196.62	-	-55.94	-71.21	-250.06
Comprehensive Income & Other	59.15	112.18	143.07	391.64	46.55	273.78
Total Common Equity	13,963	13,862	14,042	13,876	13,004	12,107
Minority Interest	1,404	1,043	724.21	1,060	1,307	1,533
Shareholders' Equity	15,367	14,906	14,767	14,936	14,311	13,640
Total Liabilities & Equity	24,538	24,456	25,045	24,868	22,372	20,591
Total Debt	3,917	3,983	4,141	3,619	2,694	1,930
Net Cash (Debt)	7,127	6,934	7,266	6,901	6,635	8,050
Net Cash Growth	6.25%	-4.57%	5.29%	4.01%	-17.58%	7.16%
Net Cash Per Share	7.93	7.53	7.81	7.37	7.09	8.58
Filing Date Shares Outstanding	888.72	908.91	923.94	932.23	929.97	932.47
Total Common Shares Outstanding	888.72	908.91	923.94	932.23	929.97	944.84
Working Capital	9,214	8,795	9,179	9,591	7,748	8,544
Book Value Per Share	15.71	15.25	15.20	14.88	13.98	12.81
Tangible Book Value	13,359	13,334	13,491	13,216	12,640	11,768
Tangible Book Value Per Share	15.03	14.67	14.60	14.18	13.59	12.45
Buildings	-	3,912	3,745	-	3,123	2,970
Machinery	-	4,817	4,551	7,577	3,764	3,216
Construction In Progress	-	257.37	289.31	602.44	554.58	385.7

Source: S&P Global Market Intelligence. Standard template. Financial Sources.